product description:

1. tetracaine hcl is synthesized from 4-butylaminobenzoic acid. the ethyl ester is formed through an acid-catalyzed esterification reaction. base-catalyzed transesterification is achieved by boiling the ethyl ester of 4-butylaminobenzoic acid with excess 2-dimethylaminoethanol in the presence of a small amount of sodium ethoxide.

2. tetracaine is the t in tac, a mixture of 5 to 12 per cent tetracaine, 5? (per myriad), a half per mille (0.5‰), or .05 per cent (1 part in 2000) adrenaline, nose & throat surgery and in the emergemcy department where numbing of the surface is needed rapidly, especially when children have been injured in the eye, ear, or other sensitive locations.

3. it is on the world health organization's list of essential medicines, a list of the most important medication needed in a basic health system.a systematic review and meta-analysis of randomised controlled trials investigated tetracaine for use in emergency departments, especially for iv cannulation in children, in view of its analgesic and cost-saving properties - however it did not find a statistically significant improvement in first attempt cannulations.

specifications:

applications:

1.tetracaine (inn, also known as amethocaine; trade name pontocaine. ametop and dicaine) is a potent local anesthetic of the ester group. it is mainly used topically in ophthalmology and as an antipruritic, and it has been used in spinal anesthesia.

2.in biomedical research, tetracaine is used to alter the function of calcium release channels (ryanodine receptors) that control the release of calcium from intracellular stores. tetracaine is an allosteric blocker of channel function. at low concentrations, tetracaine causes an initial inhibition of spontaneous calcium release events, while at high concentrations, tetracaine blocks release completely.